Published in Am J Pathol on August 01, 2003
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med (2010) 2.62
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg (2006) 1.95
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression. J Clin Epidemiol (2010) 1.75
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res (2009) 1.69
Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer (2013) 1.67
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest (2007) 1.66
MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther (2009) 1.54
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol (2010) 1.43
Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer (2014) 1.39
Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ (2009) 1.35
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene (2009) 1.34
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch (2009) 1.19
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer (2012) 1.13
Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol (2010) 1.06
Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother (2008) 1.05
Animal models of soft-tissue sarcoma. Dis Model Mech (2010) 1.01
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A (2012) 1.00
Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol (2010) 0.97
The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling. Int J Clin Exp Pathol (2013) 0.94
Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics (2011) 0.92
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget (2016) 0.91
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma (2014) 0.88
Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study. Langenbecks Arch Surg (2009) 0.87
Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med (2008) 0.86
Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Am J Surg Pathol (2011) 0.86
CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes Cancer (2011) 0.85
Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology (2015) 0.85
Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther (2011) 0.83
Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas. J Transl Med (2014) 0.79
Overexpression of atypical protein kinase C in HeLa cells facilitates macropinocytosis via Src activation. Cell Signal (2014) 0.78
Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy. BMC Med Genomics (2012) 0.78
Notch signaling in pediatric soft tissue sarcomas. BMC Med (2012) 0.77
Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer (2008) 0.77
MicroRNAs in the pathobiology of sarcomas. Lab Invest (2015) 0.75
[Sarcoma gene signatures]. Pathologe (2011) 0.75
A Case of Non-Islet Cell Tumor Hypoglycemia (NICTH) Associated with Gastrointestinal Stromal Tumor (GIST). Am J Case Rep (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A (1999) 39.79
Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A (2000) 19.39
Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A (2001) 19.30
Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics (2000) 13.33
Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch (2001) 10.93
Cancer statistics, 2002. CA Cancer J Clin (2002) 10.79
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature (1993) 5.69
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med (1998) 4.18
MALIGNANT FIBROUS XANTHOMAS. Cancer (1964) 4.10
Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol (1992) 3.52
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer (1963) 2.91
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol (1993) 2.84
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res (2001) 2.80
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
Histiocytic tumors (fibrous xanthoma and histiocytoma) in children. Cancer (1961) 1.98
Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol (2000) 1.79
Gastrointestinal stromal tumor workshop. Hum Pathol (2001) 1.70
Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res (2001) 1.66
Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res (2001) 1.60
Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol (2002) 1.46
Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res (2002) 1.37
Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn (2002) 1.15
Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer (1998) 1.14
Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol (1995) 1.13
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem (1997) 0.99
The significance of double phenotypic patterns and markers in human sarcomas. A new model of mesenchymal differentiation. Am J Pathol (1986) 0.90
Opiates and the gastrointestinal tract. Am J Gastroenterol (1980) 0.90
Primary fibrosarcoma and malignant fibrous histiocytoma of bone--a comparative ultrastructural study: evidence of a spectrum of fibroblastic differentiation. Ultrastruct Pathol (2000) 0.89
Malignant fibrous histiocytoma: an ultrastructural perspective. Ultrastruct Pathol (2001) 0.87
Chromosomal translocations in sarcomas: prospects for therapy. Trends Mol Med (2001) 0.83
Soft tissue sarcoma with additional anaplastic components. A clinicopathologic and immunohistochemical study of 27 cases. Cancer (1990) 0.79
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res (2009) 23.27
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Global mapping of protein-DNA interactions in vivo by digital genomic footprinting. Nat Methods (2009) 10.17
Coexpression analysis of human genes across many microarray data sets. Genome Res (2004) 9.38
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods (2006) 8.52
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
A three-dimensional model of the yeast genome. Nature (2010) 7.01
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics (2005) 4.98
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res (2012) 4.80
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms. Nucleic Acids Res (2005) 4.41
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet (2008) 3.76
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell (2006) 3.67
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Unsupervised segmentation of continuous genomic data. Bioinformatics (2007) 3.35
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev (2009) 2.99
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
Widely distributed noncoding purifying selection in the human genome. Proc Natl Acad Sci U S A (2007) 2.71
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68